FILANA THERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
FLNA$0.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(In thousands, except share data)
| Total | |||||
|---|---|---|---|---|---|
| Common stock · Additional · Accumulated · stockholders' | |||||
| Shares | Par value | paid-in capital | deficit | equity | |
| Balance at December 31, 2022 | 41,735,557 | 42 | 511,049 | (283,552) | 227,539 |
| Stock-based compensation for: | |||||
| Stock options for employees | — | — | 4,493 | — | 4,493 |
| Stock options for non-employees | — | — | 93 | — | 93 |
| Issuance of common stock pursuant to exercise of stock options | 501,362 | — | 2,560 | — | 2,560 |
| Net loss | — | — | — | (97,217) | (97,217) |
| Balance at December 31, 2023 | 42,236,919 | $42 | $518,195 | $(380,769) | $137,468 |
| Stock-based compensation for: | |||||
| Stock options for employees | — | — | 15,054 | — | 15,054 |
| Stock options for non-employees | — | — | 1,237 | — | 1,237 |
| Issuance of warrants | — | — | (113,363) | — | (113,363) |
| Common stock issued pursuant to warrant exercises, net of exercise costs | 5,739,247 | 6 | 123,546 | — | 123,552 |
| Derecognition of warrant liabilities upon exercise of warrants | — | — | 5,180 | — | 5,180 |
| Issuance of common stock pursuant to exercise of stock options | 227,013 | — | 918 | — | 918 |
| Net loss | — | — | — | (24,342) | (24,342) |
| Balance at December 31, 2024 | 48,203,179 | $48 | $550,767 | $(405,111) | $145,704 |
| Stock-based compensation for: | |||||
| Stock options for employees | — | — | 18,776 | — | 18,776 |
| Stock options for non-employees | — | — | 806 | — | 806 |
| Issuance of common stock pursuant to exercise of stock options | 104,717 | — | 90 | — | 90 |
| Net loss | — | — | — | (90,973) | (90,973) |
| Balance at December 31, 2025 | 48,307,896 | $48 | $570,439 | $(496,084) | $74,403 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.